Volrustomig
Based on 1 Customer Validation
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 2407760-40-9
- Molecular Weight:146.51 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
CTLA4 & PDCD1
Volrustomig potently inhibits CTLA-4 binding on PD-1-positive activated T cells (IC50 0.01 nmol/L) and is significantly less potent against PD-1-negative T cells (IC50 4.6 nmol/L)[4].
Volrustomig provides comparable sustained PD-1 binding and significantly more potent CTLA-4 binding on activated T cells compared to coadministered conventional bivalent anti-PD-1 and anti-CTLA-4 monoclonal antibodies[4].
Volrustomig (6 hours) induces >90% downregulation of cell surface PD-1 on activated T cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa_VK-CL_3bridges
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Volrustomig (anti-CTLA4) (HY-P990690). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Volrustomig (anti-PDCD1) (HY-P990690). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2407760-40-9
-
Appearance Liquid
-
Molecular Weight 146.51 kDa
-
Color Colorless to light yellow
-
Synonyms
MEDI-5752
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[3]. Bose CK, et al. Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer. J Gynecol Oncol. 2024;35(4):e82. [Content Brief]
[4]. Tran B, et al. Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody. Clin Cancer Res. Published online February 17, 2026. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)